HUE040427T2 - Nukleáris transzportmodulátorok és felhasználásuk - Google Patents

Nukleáris transzportmodulátorok és felhasználásuk

Info

Publication number
HUE040427T2
HUE040427T2 HUE13779943A HUE13779943A HUE040427T2 HU E040427 T2 HUE040427 T2 HU E040427T2 HU E13779943 A HUE13779943 A HU E13779943A HU E13779943 A HUE13779943 A HU E13779943A HU E040427 T2 HUE040427 T2 HU E040427T2
Authority
HU
Hungary
Prior art keywords
nuclear transport
transport modulators
modulators
nuclear
transport
Prior art date
Application number
HUE13779943A
Other languages
English (en)
Hungarian (hu)
Inventor
Vincent Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE040427(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HUE040427T2 publication Critical patent/HUE040427T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13779943A 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk HUE040427T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE040427T2 true HUE040427T2 (hu) 2019-03-28

Family

ID=49448240

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE13779943A HUE040427T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzportmodulátorok és felhasználásuk
HUE18164757A HUE050452T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18164757A HUE050452T2 (hu) 2012-05-09 2013-05-09 Nukleáris transzport modulátorok és alkalmazásuk

Country Status (32)

Country Link
US (10) US9266843B2 (forum.php)
EP (3) EP2858991B1 (forum.php)
JP (5) JP6195909B2 (forum.php)
KR (5) KR20200115688A (forum.php)
CN (1) CN104428295B (forum.php)
AU (5) AU2013259384B2 (forum.php)
BR (1) BR112014027860B8 (forum.php)
CA (1) CA2872190C (forum.php)
CL (1) CL2014003054A1 (forum.php)
CO (1) CO7190242A2 (forum.php)
CY (2) CY1120832T1 (forum.php)
DK (2) DK3404027T3 (forum.php)
EA (1) EA036639B1 (forum.php)
ES (3) ES2702279T3 (forum.php)
GE (1) GEP20237477B (forum.php)
HR (2) HRP20181838T1 (forum.php)
HU (2) HUE040427T2 (forum.php)
IN (1) IN2014DN09434A (forum.php)
LT (2) LT2858991T (forum.php)
ME (1) ME03795B (forum.php)
MX (1) MX364992B (forum.php)
NZ (1) NZ702663A (forum.php)
PE (1) PE20150128A1 (forum.php)
PL (2) PL2858991T3 (forum.php)
PT (2) PT2858991T (forum.php)
RS (2) RS60424B1 (forum.php)
SG (1) SG11201407268SA (forum.php)
SI (2) SI3404027T1 (forum.php)
SM (2) SMT202000347T1 (forum.php)
UA (2) UA118085C2 (forum.php)
WO (1) WO2013170068A2 (forum.php)
ZA (1) ZA202004892B (forum.php)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
CA2842362C (en) 2011-07-29 2020-06-16 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof
PE20141003A1 (es) 2011-07-29 2014-09-02 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos
PT2858991T (pt) * 2012-05-09 2018-12-17 Biogen Ma Inc Moduladores do transporte nuclear e usos dos mesmos
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CA2915365C (en) 2013-06-21 2022-08-16 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
CN106463191B (zh) * 2014-05-13 2018-12-14 Qsa全球有限公司 用于增强型铱伽马辐射源的装置和方法
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US10519139B2 (en) 2014-08-15 2019-12-31 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017035116A1 (en) * 2015-08-25 2017-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017117535A1 (en) * 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017151587A1 (en) * 2016-02-29 2017-09-08 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones
CA3013799A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
EP3448234A4 (en) 2016-04-30 2019-05-01 Envision Diagnostics, Inc. MEDICAL DEVICES, SYSTEMS AND METHODS FOR PERFORMING EYE EXAMINATIONS AND EYES TRACKING
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MX2020007479A (es) 2018-01-10 2020-11-24 Xwpharma Ltd Profármacos de ketamina, composiciones y usos de los mismos.
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
CN109928939A (zh) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 一种2,2,6,6-四甲基吗啉的制备方法
MX2021013211A (es) * 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
CN111145135B (zh) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 一种图像去扰处理方法、装置、设备及存储介质
JP7658052B2 (ja) 2021-04-01 2025-04-08 アルプスアルパイン株式会社 操作検出装置
CN117881394A (zh) 2021-08-13 2024-04-12 凯瑞康宁生物工程（武汉）有限公司 氯胺酮衍生物的药物组合物和口服剂型
WO2023172855A2 (en) * 2022-03-07 2023-09-14 Kaohsiung Medical University Methods for treating hepatitis b virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
ES2273364T3 (es) 1996-04-04 2007-05-01 SHIONOGI & CO., LTD. Compuestos dde d[cefemo y composiciones farmaceuticas que contienen estos compuestos.
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
EP0913392B1 (en) 1996-04-25 2003-07-02 Nissan Chemical Industries, Limited Ethylene derivatives and pest controlling agents
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1598067B1 (en) * 2000-09-29 2009-05-06 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage for the treatment of malaria
JP3608050B2 (ja) 2001-07-24 2005-01-05 トヨタ自動車株式会社 ロールオーバ判別装置
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
KR20050062645A (ko) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 신경병증의 예방 또는 치료제
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MXPA06013534A (es) 2004-05-26 2007-05-10 Eisai R&D Man Co Ltd Compuesto de cinamida.
US7902367B2 (en) 2004-08-11 2011-03-08 Kyorin Pharmaceutical Co., Ltd. Cyclic amino benzoic acid derivative
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
MX2008011221A (es) 2006-03-09 2008-09-11 Eisai R&D Man Co Ltd Compuestos de cinamida policiclicos.
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
MX2008013292A (es) 2006-04-18 2008-11-14 Nippon Chemiphar Co Agente activador para el receptor ? activado por el proliferador de peroxisoma.
EP2030974B1 (en) 2006-06-13 2016-02-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Thiazole non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
CN100503571C (zh) 2006-07-12 2009-06-24 中国药科大学 四氢异喹啉类衍生物、其制备方法及其医药用途
JP5254228B2 (ja) 2006-07-27 2013-08-07 株式會社アモーレパシフィック バニロイド受容体アンタゴニストとしての、新規化合物、その異性体またはその薬学的に許容される塩；並びにそれを含む医薬組成物
ATE532770T1 (de) 2006-09-05 2011-11-15 Kyowa Hakko Kirin Co Ltd Imidazolderivat
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
WO2009003921A1 (en) * 2007-07-04 2009-01-08 Neurosearch A/S Novel pyrazole derivatives useful as potassium channel modulators
US20110009374A1 (en) 2009-07-09 2011-01-13 Keller Brian C Method of wound healing and scar modulation
US8518968B2 (en) * 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
AU2012207565B2 (en) 2011-01-17 2016-04-07 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
PE20141003A1 (es) 2011-07-29 2014-09-02 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos
CA2842362C (en) 2011-07-29 2020-06-16 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
PT2858991T (pt) 2012-05-09 2018-12-17 Biogen Ma Inc Moduladores do transporte nuclear e usos dos mesmos
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
CA2915365C (en) 2013-06-21 2022-08-16 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
US10519139B2 (en) 2014-08-15 2019-12-31 Karyopharm Therapeutics Inc. Polymorphs of Selinexor
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11034675B2 (en) 2016-01-08 2021-06-15 Dr. Reddy's Laboratories Limited Solid forms of Selinexor and process for their preparation
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3565813A1 (en) 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
US20210251968A1 (en) 2021-08-19
CN104428295A (zh) 2015-03-18
US10335393B2 (en) 2019-07-02
US10058535B2 (en) 2018-08-28
CY1120832T1 (el) 2019-12-11
AU2021221398A1 (en) 2021-09-16
KR20200041984A (ko) 2020-04-22
ES2794866T3 (es) 2020-11-19
PL3404027T3 (pl) 2020-09-21
SMT201800686T1 (it) 2019-01-11
US10925859B2 (en) 2021-02-23
US20150111893A1 (en) 2015-04-23
KR102163377B1 (ko) 2020-10-08
WO2013170068A2 (en) 2013-11-14
BR112014027860A2 (pt) 2017-06-27
AU2019272017A1 (en) 2019-12-19
JP6818849B2 (ja) 2021-01-20
CA2872190A1 (en) 2013-11-14
IN2014DN09434A (forum.php) 2015-07-17
HRP20200876T1 (hr) 2020-09-04
KR20200118240A (ko) 2020-10-14
EA201492050A1 (ru) 2015-07-30
LT2858991T (lt) 2018-11-26
SMT202000347T1 (it) 2020-07-08
PT3404027T (pt) 2020-03-30
WO2013170068A3 (en) 2014-02-20
UA118085C2 (uk) 2018-11-26
JP2018012715A (ja) 2018-01-25
JP2018172444A (ja) 2018-11-08
BR112014027860B8 (pt) 2024-04-30
AU2018201012A1 (en) 2018-03-01
EA036639B1 (ru) 2020-12-02
US20130317031A1 (en) 2013-11-28
US9096543B2 (en) 2015-08-04
CA2872190C (en) 2024-06-25
AU2018201012B2 (en) 2019-12-05
KR102165177B1 (ko) 2020-10-13
RS60424B1 (sr) 2020-07-31
JP2021063104A (ja) 2021-04-22
EP3663291A1 (en) 2020-06-10
GEP20237477B (en) 2023-03-27
CN104428295B (zh) 2017-08-08
AU2013259384A1 (en) 2014-12-18
ES3016982T3 (en) 2025-05-12
HK1209420A1 (en) 2016-04-01
LT3404027T (lt) 2020-07-10
EP3404027A1 (en) 2018-11-21
KR20200115688A (ko) 2020-10-07
US20200230110A1 (en) 2020-07-23
UA124922C2 (uk) 2021-12-15
KR20200041986A (ko) 2020-04-22
US20190008833A1 (en) 2019-01-10
AU2016222459A1 (en) 2016-09-22
SI3404027T1 (sl) 2020-08-31
JP2015516434A (ja) 2015-06-11
BR112014027860B1 (pt) 2022-03-08
PE20150128A1 (es) 2015-02-23
CL2014003054A1 (es) 2015-05-15
US20200038373A1 (en) 2020-02-06
EP2858991A2 (en) 2015-04-15
KR102095429B1 (ko) 2020-03-31
MX2014013551A (es) 2015-01-16
KR20150018809A (ko) 2015-02-24
JP2020037585A (ja) 2020-03-12
ES2702279T3 (es) 2019-02-28
US11318120B2 (en) 2022-05-03
EP3663291B1 (en) 2024-12-18
PL2858991T3 (pl) 2019-01-31
DK3404027T3 (da) 2020-06-02
US20180289675A1 (en) 2018-10-11
CY1123476T1 (el) 2022-03-24
US10617677B2 (en) 2020-04-14
AU2013259384B2 (en) 2016-06-02
US9585874B2 (en) 2017-03-07
SI2858991T1 (sl) 2018-12-31
US10722497B2 (en) 2020-07-28
US9861614B2 (en) 2018-01-09
AU2019272017B2 (en) 2021-05-27
KR102223028B1 (ko) 2021-03-03
DK2858991T3 (en) 2018-11-26
JP6195909B2 (ja) 2017-09-13
ME03795B (me) 2021-04-20
US20170319551A1 (en) 2017-11-09
SG11201407268SA (en) 2015-01-29
NZ702663A (en) 2017-03-31
EP3404027B1 (en) 2020-03-04
US20160354347A1 (en) 2016-12-08
MX364992B (es) 2019-05-17
EP2858991B1 (en) 2018-08-08
AU2021221398B2 (en) 2023-08-17
CO7190242A2 (es) 2015-02-19
ZA202004892B (en) 2023-03-29
RS58058B1 (sr) 2019-02-28
US9266843B2 (en) 2016-02-23
HUE050452T2 (hu) 2021-03-29
PT2858991T (pt) 2018-12-17
US20160145246A1 (en) 2016-05-26
HRP20181838T1 (hr) 2018-12-28

Similar Documents

Publication Publication Date Title
ZA202004892B (en) Nuclear transport modulators and uses thereof
IL261612A (en) Nuclear transfer modulators and their uses
HUE036058T2 (hu) Hidrazidtartalmú magtranszportmodulátorok és alkalmazásuk
HUE037021T2 (hu) DLL3- modulátorok és eljárások alkalmazásukra
HUE054881T2 (hu) Nyomtatási rendszer és eljárás
HUE054444T2 (hu) Prolinnal lezárt kapcsos peptidek és felhasználásuk
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
HUE046559T2 (hu) Policiklusos karbamoilpiridon vegyületek és gyógyszerészeti alkalmazásuk
SG10201609097PA (en) Nuclear transport modulators and uses thereof
DK2872419T3 (da) Fordelingsbeholder og tilsvarende fremgangsmåde
HUE050797T2 (hu) T-sejt módosító vegyületek és alkalmazásaik
BR112014000049A2 (pt) pirrolotriazinas substituídas com hidroximelilarilo e sua utilização
HUE042531T2 (hu) ASIC1-ellenes antitestek és alkalmazásaik
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
EP2855506A4 (en) PEPTIDE AND USE THEREOF
EP2800947A4 (en) COMBINED PICTURE DEVICE AND DISTANCE KNIFE
FR2989572B1 (fr) Sparadrap et son utilisation
HUE046427T2 (hu) Injektálható antibiotikus készítmények és azok alkalmazása
FI9978U1 (fi) Istutusastia ja istutusjärjestelmä
FI9847U1 (fi) Kantoväline ja sen aihio
CO6960538A2 (es) Moduladores del transporte nuclear y uso de los mismos